Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs?
Eli Lilly stock is trending lower in December, but an FDA decision will keep compounders from making tirzepatide. Is Lilly stock a buy?
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Eli Lilly stock is trending lower in December, but an FDA decision will keep compounders from making tirzepatide. Is Lilly stock a buy?